NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-20-223 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences
Notice NOT-HL-20-794 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-213 from the NIH Guide for Grants and Contracts. The goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32) program is to develop a diverse pool of well-trained scientists available to address the Nations biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.
Notice NOT-HG-20-042 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-225 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
Funding Opportunity PAR-20-224 from the NIH Guide for Grants and Contracts. Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS. The nexus with drug abuse should be clearly described. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support research approaches, both basic and clinical, which have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, improving therapies for HIV, reducing the impact of comorbid conditions, and ultimately, eradicating HIV.
Funding Opportunity PAR-20-221 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.
Funding Opportunity RFA-HD-21-016 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to invite applications to form a research network to conduct multisite clinical studies in pediatric critical care medicine. The Network will be comprised of a Data Coordinating Center (DCC) and at least seven Clinical Sites. The Network is designed to investigate the efficacy of treatment and management strategies to care for critically ill and injured children, as well as to better understand the pathophysiological bases of critical illness and injury in childhood.
Notice NOT-DK-20-032 from the NIH Guide for Grants and Contracts
Notice NOT-DK-20-033 from the NIH Guide for Grants and Contracts
Notice NOT-MH-20-051 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-112 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-20-222 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Notice NOT-AG-20-026 from the NIH Guide for Grants and Contracts
Notice NOT-AI-20-053 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-072 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-070 from the NIH Guide for Grants and Contracts
Notice NOT-MH-20-054 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-220 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to solicit new Institutional Network Awards (U2C/TL1) to cultivate a highly integrated cohort of people and resources to accelerate kidney, urologic and hematologic research. To maximize integration and promote a true trainee community, Institutions are invited to submit a single, unified U2C/TL1 application to engage, recruit, prepare and sustain the next generation of kidney, urology, and hematology researchers. Applications covering a single metropolitan area are strongly encouraged (see Section III.3).
Notice NOT-MH-20-057 from the NIH Guide for Grants and Contracts